Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol

International Journal of Antimicrobial Agents

Volumn 49, Issue 3, 2017, Pages 321-326

  Wei, Wen juan ^a   Yang, Hai fei ^b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Acinetobacter baumannii; Antimicrobial synergy; Chloramphenicol; Colistin

Indexed keywords

CHLORAMPHENICOL; COLISTIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CHLORAMPHENICOL; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 85015591669     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.11.031     Document Type: Article

References (22)

1. [1] Yang, H., Chen, G., Hu, L., Liu, Y., Cheng, J., Li, H., et al. In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 45 (2015), 188–191.
2. [2] Li, J., Rayner, C.R., Nation, R.L., Owen, R.J., Spelman, D., Tan, K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006), 2946–2950.
3. [3] Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.
4. [4] Falgenhauer, L., Waezsada, S.E., Yao, Y., Imirzalioglu, C., Käsbohrer, A., Roesler, U., et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect Dis 16 (2016), 282–283.
5. [5] Maviglia, R., Nestorini, R., Pennisi, M., Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets 10 (2009), 895–905.
6. [6] Čivljak, R., Giannella, M., Di Bella, S., Petrosillo, N., Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century. Expert Rev Anti Infect Ther 12 (2014), 249–264.
7. [7] Abdul Rahim, N., Cheah, S.E., Johnson, M.D., Yu, H., Sidjabat, H.E., Boyce, J., et al. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics—polymyxin B and chloramphenicol. J Antimicrob Chemother 70 (2015), 2589–2597.
8. [8] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25. Wayne, PA: CLSI, 2015.
9. [9] Wei, W., Yang, H., Liu, Y., Ye, Y., Li, J., In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother 28 (2016), 159–163.
10. [10] Steinbach, W.J., Stevens, D.A., Denning, D.W., Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37:Suppl. 3 (2003), S188–224.
11. [11] Milne, K.E., Gould, I.M., Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 65 (2010), 82–90.
12. [12] Di, X., Wang, R., Liu, B., Zhang, X., Ni, W., Wang, J., et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa. J Antibiot (Tokyo) 68 (2015), 551–555.
13. [13] Zhao, X., Drlica, K., Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33:Suppl. 3 (2001), S147–56.
14. [14] Zhanel, G.G., Mayer, M., Laing, N., Adam, H.J., Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (polymyxin E), meropenem, piperacillin–tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006), 2228–2230.
15. [15] Bergen, P.J., Forrest, A., Bulitta, J.B., Tsuji, B.T., Sidjabat, H.E., Paterson, D.L., et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55 (2011), 5134–5142.
16. [16] Yang, H., Lv, N., Hu, L., Liu, Y., Cheng, J., Ye, Y., et al. In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model. Infect Dis (Lond) 48 (2016), 189–194.
17. [17] Wei, W., Yang, H., Hu, L., Ye, Y., Li, J., Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: in vitro and in a Galleria mellonella model. J Microbiol Immunol Infect, 2015, 10.1016/j.jmii.2015.10.010 Epub ahead of print.
18. [18] Gerber, A.U., Craig, W.A., Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice. J Lab Clin Med 100 (1982), 671–681.
19. [19] Tan, C.H., Li, J., Nation, R.L., Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 51 (2007), 3413–3415.
20. [20] Conlon, B.P., Nakayasu, E.S., Fleck, L.E., LaFleur, M.D., Isabella, V.M., Coleman, K., et al. Persister cells and the paradox of chronic infections. Nature 503 (2013), 365–370.
21. [21] Hobby, G.L., Meyer, K., Chaffee, E., Observations on the mechanism of action of penicillin. Proc Soc Exp Biol Med 50 (1942), 281–285.
22. [22] Wood, T.K., Knabel, S.J., Kwan, B.W., Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79 (2013), 7116–7121.